1
|
|
2
|
Martin A, Berger JM, Sellers JR, Ostankovitch M. Mechanisms and Functional Diversity of Macromolecular Remodeling by ATP-Dependent Motors. J Mol Biol 2016; 428:1819-21. [PMID: 27113061 DOI: 10.1016/j.jmb.2016.04.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2016] [Indexed: 10/21/2022]
Affiliation(s)
| | - James M Berger
- The Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
| | - James R Sellers
- National Heart, Lung and Blood Institute, Bethesda, MD 20814, USA.
| | | |
Collapse
|
3
|
Affiliation(s)
- Ye-Guang Chen
- School of Life Sciences, Tsinghua University, Beijing 100084, China.
| | - Elena Ezhkova
- Icahn School of Medicine at Mount Sinai, New York, NY 10128, USA.
| | | |
Collapse
|
4
|
Ostankovitch M, Stagljar I. Omics Approaches Deciphering Molecular Function in Large Biological Systems. J Mol Biol 2015; 427:3351-5. [DOI: 10.1016/j.jmb.2015.09.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
5
|
|
6
|
|
7
|
Ostankovitch M, Debatisse M. From the replicon to replication programs in space and time: regulation of DNA replication and implications for genomic instability. J Mol Biol 2013; 425:4659-62. [PMID: 24207007 DOI: 10.1016/j.jmb.2013.10.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Marina Ostankovitch
- Journal of Molecular Biology, Elsevier Inc., 600 Technology Square, Cambridge, MA 02139, USA.
| | | |
Collapse
|
8
|
Ostankovitch M. Dynamic Mechanisms in the Life Cycle of an RNA Molecule. J Mol Biol 2013; 425:3747-9. [DOI: 10.1016/j.jmb.2013.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2013] [Revised: 08/28/2013] [Accepted: 09/02/2013] [Indexed: 11/26/2022]
|
9
|
|
10
|
Ostankovitch M, Altrich-Vanlith M, Robila V, Engelhard VH. N-glycosylation enhances presentation of a MHC class I-restricted epitope from tyrosinase. J Immunol 2009; 182:4830-5. [PMID: 19342661 DOI: 10.4049/jimmunol.0802902] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
We recently demonstrated that the mechanism of processing of an HLA-A*0201-restricted peptide epitope, Tyr(369)(D), derived from the membrane protein tyrosinase, involves retrotranslocation of glycosylated molecules from the endoplasmic reticulum to the cytosol, removal of an N-linked carbohydrate from Asn(371) by peptide N-glycanase, proteolysis by the proteasome and other proteases, and retransport of the resulting peptides into the endoplasmic reticulum for association with HLA-A*0201. Carbohydrate removal results in deamidation of Asn(371) to aspartic acid. The asparagine-containing homolog of this peptide, Tyr(369)(N), is not presented by tyrosinase-expressing cells, and this has been presumed to be due to quantitative glycosylation of Asn(371). Although examining cytosolic intermediates that accumulated in human melanoma cells treated with proteasome inhibitors, we were surprised to find both molecules that had been deglycosylated by peptide N-glycanase and a large number of molecules that had not been previously glycosylated. The failure of Tyr(369)(N) to be processed and presented from these latter molecules may be partially due to a process of deamidation independent of glycosylation. However, we also established that proteasomes degrade tyrosinase molecules that are still glycosylated, giving rise to a set of discrete intermediates that are not observed when unglycosylated molecules are degraded. We propose that Tyr(369)(N) fails to be presented because unglycosylated tyrosinase is degraded rapidly and relatively nonselectively. In contrast, glycosylation alters the selectivity of tyrosinase processing by the proteasome, enhancing the production or survival of Tyr(369)(D).
Collapse
Affiliation(s)
- Marina Ostankovitch
- Department of Microbiology, Carter Immunology Center, University of Virginia, Charlottesville, VA 22908, USA
| | | | | | | |
Collapse
|
11
|
Robila V, Ostankovitch M, Altrich-VanLith ML, Theos AC, Drover S, Marks MS, Restifo N, Engelhard VH. MHC class II presentation of gp100 epitopes in melanoma cells requires the function of conventional endosomes and is influenced by melanosomes. J Immunol 2008; 181:7843-52. [PMID: 19017974 PMCID: PMC2659719 DOI: 10.4049/jimmunol.181.11.7843] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Many human solid tumors express MHC class II (MHC-II) molecules, and proteins normally localized to melanosomes give rise to MHC-II-restricted epitopes in melanoma. However, the pathways by which this response occurs have not been defined. We analyzed the processing of one such epitope, gp100(44-59), derived from gp100/Pmel17. In melanomas that have down-regulated components of the melanosomal pathway, but constitutively express HLA-DR*0401, the majority of gp100 is sorted to LAMP-1(high)/MHC-II(+) late endosomes. Using mutant gp100 molecules with altered intracellular trafficking, we demonstrate that endosomal localization is necessary for gp100(44-59) presentation. By depletion of the AP-2 adaptor protein using small interfering RNA, we demonstrate that gp100 protein internalized from the plasma membrane to such endosomes is a major source for gp100(44-59) epitope production. The gp100 trapped in early endosomes gives rise to epitopes that are indistinguishable from those produced in late endosomes but their production is less sensitive to inhibition of lysosomal proteases. In melanomas containing melanosomes, gp100 is underrepresented in late endosomes, and accumulates in stage II melanosomes devoid of MHC-II molecules. The gp100(44-59) presentation is dramatically reduced, and processing occurs entirely in early endosomes or stage I melanosomes. This occurrence suggests that melanosomes are inefficient Ag-processing compartments. Thus, melanoma de-differentiation may be accompanied by increased presentation of MHC-II restricted epitopes from gp100 and other melanosome-localized proteins, leading to enhanced immune recognition.
Collapse
Affiliation(s)
- Valentina Robila
- Department of Microbiology and Carter Immunology Center, University of Virginia School of Medicine, Charlottesville VA 22908
| | - Marina Ostankovitch
- Department of Microbiology and Carter Immunology Center, University of Virginia School of Medicine, Charlottesville VA 22908
| | - Michelle L. Altrich-VanLith
- Department of Microbiology and Carter Immunology Center, University of Virginia School of Medicine, Charlottesville VA 22908
| | - Alexander C. Theos
- Dept. of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia PA 19104
| | - Sheila Drover
- Division of Biomedical Sciences, Memorial University of Newfoundland, St. John's, NF Canada A1B3V6
| | - Michael S. Marks
- Dept. of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia PA 19104
| | - Nicholas Restifo
- National Cancer Institute, National Institutes of Health Bethesda, MD 20892
| | - Victor H. Engelhard
- Department of Microbiology and Carter Immunology Center, University of Virginia School of Medicine, Charlottesville VA 22908
| |
Collapse
|
12
|
Altrich-VanLith ML, Ostankovitch M, Polefrone JM, Mosse CA, Shabanowitz J, Hunt DF, Engelhard VH. Processing of a Class I-Restricted Epitope from Tyrosinase Requires Peptide N-Glycanase and the Cooperative Action of Endoplasmic Reticulum Aminopeptidase 1 and Cytosolic Proteases. J Immunol 2006; 177:5440-50. [PMID: 17015730 DOI: 10.4049/jimmunol.177.8.5440] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Although multiple components of the class I MHC processing pathway have been elucidated, the participation of nonproteasomal cytosolic enzymes has been largely unexplored. In this study, we provide evidence for multiple cytosolic mechanisms in the generation of an HLA-A*0201-associated epitope from tyrosinase. This epitope is presented in two isoforms containing either Asn or Asp, depending on the structure of the tyrosinase precursor. We show that deamidation of Asn to Asp is dependent on glycosylation in the endoplasmic reticulum (ER), and subsequent deglycosylation by peptide-N-glycanase in the cytosol. Epitope precursors with N-terminal extensions undergo a similar process. This is linked to an inability of ER aminopeptidase 1 to efficiently remove N-terminal residues, necessitating processing by nonproteasomal peptidases in the cytosol. Our work demonstrates that processing of this tyrosinase epitope involves recycling between the ER and cytosol, and an obligatory interplay between enzymes involved in proteolysis and glycosylation/deglycosylation located in both compartments.
Collapse
Affiliation(s)
- Michelle L Altrich-VanLith
- Carter Immunology Center and Department of Microbiology, University of Virginia, Charlottesville, VA 22908-1386, USA
| | | | | | | | | | | | | |
Collapse
|
13
|
Engelhard VH, Altrich-Vanlith M, Ostankovitch M, Zarling AL. Post-translational modifications of naturally processed MHC-binding epitopes. Curr Opin Immunol 2005; 18:92-7. [PMID: 16343885 DOI: 10.1016/j.coi.2005.11.015] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2005] [Accepted: 11/25/2005] [Indexed: 01/21/2023]
Abstract
A variety of different post-translational modifications of peptides displayed by class I and II MHC molecules have now been described. Some modifications promote the binding of peptides to MHC molecules, and might also influence the ability of the peptide to be produced by antigen processing pathways. In some instances, the antigen processing components themselves are actually responsible for generating post-translational modifications. Finally, evidence is accumulating that modifications can be altered as a consequence of inflammation, transformation, apoptosis and aging. This leads to altered repertories of MHC-associated peptides, which may be important in immune responses associated with autoimmune diseases, infection and cancer.
Collapse
Affiliation(s)
- Victor H Engelhard
- Carter Center for Immunology Research and the Department of Microbiology, University of Virginia School of Medicine, Charlottesville, Virginia, 22908, USA.
| | | | | | | |
Collapse
|
14
|
Ostankovitch M, Robila V, Engelhard VH. Regulated folding of tyrosinase in the endoplasmic reticulum demonstrates that misfolded full-length proteins are efficient substrates for class I processing and presentation. J Immunol 2005; 174:2544-51. [PMID: 15728460 DOI: 10.4049/jimmunol.174.5.2544] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Short-lived protein translation products have been proposed to be the principal substrates that enter the class I MHC processing and presentation pathway. However, the biochemical nature of these substrates is poorly defined. Whether the major processing substrates are misfolded full-length proteins, or alternatively, aberrantly initiated or truncated polypeptides still remains to be addressed. To examine this, we used melanoma in which one-third of wild-type tyrosinase molecules were correctly folded and localized beyond the Golgi, while the remainder were present in the endoplasmic reticulum in an unfolded/misfolded state. Increasing the efficiency of tyrosinase folding using chemical chaperones led to a reduction in the level of substrate available to the proteasome and decreased the expression of a tyrosinase-derived epitope. Conversely, in transfectants expressing tyrosinase mutants that are completely misfolded, both proteasome substrate and epitope presentation were significantly enhanced. Proteasome substrate availability was a consequence of misfolding and not simply due to retention in the endoplasmic reticulum. Thus, the extent of folding/misfolding of a full-length protein is an important determinant of the level of epitope presentation.
Collapse
Affiliation(s)
- Marina Ostankovitch
- Carter Immunology Center and Department of Microbiology, University of Virginia, Charlottesville, VA 22908, USA
| | | | | |
Collapse
|
15
|
Buzyn A, Petit F, Ostankovitch M, Figueiredo S, Varet B, Guillet JG, Ameisen JC, Estaquier J. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: A mechanism of tumor immune escape in leukemia patients. Blood 1999; 94:3135-40. [PMID: 10556200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023] Open
Abstract
There is evidence from bone marrow transplantation that T cells may be involved in the immunologic control of leukemia. But many patients relapse despite a potent graft-versus-leukemia effect mediated by allogeneic T cells. The expression of the FasL protein has been suggested as a mechanism of tumor immune escape. We, therefore, evaluated the capacity of leukemic cells from patients with acute or chronic myelogenous leukemia to escape the allogeneic or autologous immune response by bearing the FasL molecule. Although almost all leukemic cells express the 37-kD form of FasL, only 54% of acute myeloblastic leukemia and 27% of chronic myeloid leukemia (CML) cells bore a FasL with killing properties, as assessed by the ability of leukemic cells to cause the apoptosis of a Fas-sensitive target cell line or autologous activated T cells in 3 tested leukemic cases. Experiments with a recombinant Fas-Fc molecule confirmed the role of Fas/FasL in leukemic-mediated cell death. Only CML leukemic cells from certain individuals contained the 26-kD truncated form of FasL. Thus, myeloid leukemic cells from some, but not all patients can set up a mechanism of immune escape involving the Fas/FasL pathway. This leukemic escape may have implications for patients eligible for adoptive cellular immunotherapy.
Collapse
Affiliation(s)
- A Buzyn
- INSERM Unité 445, ICGM, Hôpital Cochin; INSERM E 99-22, Faculté de Médecine Bichat, Paris, France.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Lauvau G, Kakimi K, Niedermann G, Ostankovitch M, Yotnda P, Firat H, Chisari FV, van Endert PM. Human transporters associated with antigen processing (TAPs) select epitope precursor peptides for processing in the endoplasmic reticulum and presentation to T cells. J Exp Med 1999; 190:1227-40. [PMID: 10544195 PMCID: PMC2195672 DOI: 10.1084/jem.190.9.1227] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/1998] [Accepted: 08/26/1999] [Indexed: 01/12/2023] Open
Abstract
Antigen presentation by major histocompatibility complex (MHC) class I molecules requires peptide supply by the transporters associated with antigen processing (TAPs), which select substrates in a species- and, in the rat, allele-specific manner. Conflicts between TAPs and MHC preferences for COOH-terminal peptide residues in rodent cells strongly reduce the efficiency of MHC class I antigen presentation. Although human TAP is relatively permissive, some peptide ligands for human histocompatibility leukocyte antigen class I molecules are known to possess very low TAP affinities; the significance of these in vitro findings for cellular antigen presentation is not known. We studied two naturally immunodominant viral epitopes presented by HLA-A2 that display very low affinities for human TAP. Low TAP affinities preclude minimal epitope access to the endoplasmic reticulum (ER) and assembly with HLA-A2 in vitro, as well as presentation by minigene-expressing cells to cytotoxic T lymphocytes. However, NH(2)-terminally but not COOH-terminally extended epitope variants with higher TAP affinities assemble in vitro and are presented to cytotoxic T lymphocytes with high efficiency. Thus, human TAP can influence epitope selection and restrict access to the ER to epitope precursors. Analysis of TAP affinities of a panel of viral epitopes suggests that TAP selection of precursors may be a common phenomenon for HLA-A2-presented epitopes. We also analyzed HLA-A2-eluted peptides from minigene-expressing cells and show that an NH(2)-terminally extended variant with low A2 binding affinity undergoes ER processing, whereas another with high affinity is presented unmodified. Therefore, the previously reported aminopeptidase activity in the ER can also act on TAP-translocated peptides.
Collapse
Affiliation(s)
- Grégoire Lauvau
- Institut National de la Santé et Recherche Medicale (INSERM) U25, Hôpital Necker, 75015 Paris, France
| | | | | | | | - Patricia Yotnda
- Institut Pasteur, Département SIDA-Rétrovirus, Unité d'Immunité Cellulaire Antivirale, 75724 Paris cedex 15, France
| | - Hüseyin Firat
- Institut Pasteur, Département SIDA-Rétrovirus, Unité d'Immunité Cellulaire Antivirale, 75724 Paris cedex 15, France
| | | | - Peter M. van Endert
- Institut National de la Santé et Recherche Medicale (INSERM) U25, Hôpital Necker, 75015 Paris, France
| |
Collapse
|
17
|
Chassin D, Andrieu M, Cohen W, Culmann-Penciolelli B, Ostankovitch M, Hanau D, Guillet JG. Dendritic cells transfected with the nef genes of HIV-1 primary isolates specifically activate cytotoxic T lymphocytes from seropositive subjects. Eur J Immunol 1999; 29:196-202. [PMID: 9933101 DOI: 10.1002/(sici)1521-4141(199901)29:01<196::aid-immu196>3.0.co;2-4] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The HIV-1 Nef protein down-modulates surface expression of MHC class I proteins. Primary infected T lymphocytes thus escape lysis by cytotoxic T lymphocytes (CTL). In contrast, during HIV-1 infection there are strong CTL responses to several HIV proteins, and there is mounting evidence that CTL are critical for controlling the virus. The present study was carried out to assess Nef protein-cell interaction as it occurs in naturally infected antigen-presenting cells. To evaluate the presentation of peptides derived from viral antigen to CTL, we transfected nef genes obtained from peripheral blood mononuclear cells of HIV-1-seropositive subjects into dendritic cells isolated from monocytes of healthy donors. We demonstrate that expression and subsequent processing of Nef by transfected dendritic cells did not alter the presentation of an immunodominant epitope of Nef to CTL of HIV+ subjects. However, mutations in nef gene sequences from primary isolates may abolish this presentation by a mechanism that probably interferes with protein processing.
Collapse
Affiliation(s)
- D Chassin
- Laboratoire d'Immunologie des Pathologies Infectieuses et Tumorales, INSERM U445, ICGM, Université René Descartes, Paris, France.
| | | | | | | | | | | | | |
Collapse
|
18
|
Buzyn A, Ostankovitch M, Varet B, Guillet JG. [Outlook for cellular adoptive or vaccine immunotherapy for chronic myeloid leukemia]. Hematol Cell Ther 1998; 40:222-3. [PMID: 9844815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Affiliation(s)
- A Buzyn
- Service d'Hématologie Adultes, Hôpital Necker, Paris, France
| | | | | | | |
Collapse
|
19
|
Ostankovitch M, Buzyn A, Bonhomme D, Connan F, Bouscary D, Heshmati F, Dreyfus F, Choppin J, Guillet JG. Antileukemic HLA-restricted T-cell clones generated with naturally processed peptides eluted from acute myeloblastic leukemia blasts. Blood 1998; 92:19-24. [PMID: 9639494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Recent studies have shown that transfusions of HLA-compatible donor lymphocytes may induce complete remission in marrow-grafted patients with relapses of acute myeloblastic leukemia (AML). We investigated the in vitro generation of antileukemia T-cell clones obtained from the peripheral blood mononuclear cells of a partially HLA-compatible donor (HLA-A2 and B7 molecules in common with the leukemic blasts) after stimulation with a pool of naturally processed peptides extracted from leukemic blast cells collected at diagnosis from a patient with hyperleucocytosis AML. We recovered a significant quantity of peptides that bound to the HLA-A2 or HLA-B7 molecules that were able to induce cytolytic T-lymphocyte (CTL) lines and clones specific for the eluted AML peptides and restricted to the HLA-A2 or B7 molecules. Such CTL line did not recognize the patient's nonleukemic cells, and one clone was able to interact with the leukemic blasts from which the naturally processed peptides had been eluted. Such T-cell clones might provide a rationale for the development of adoptive immunotherapy and could be used to improve the efficiency of HLA-compatible T-lymphocyte transfusions and the graft-versus-leukemia response in patients with AML.
Collapse
Affiliation(s)
- M Ostankovitch
- Institut Cochin de Génétique Moléculaire, INSERM U445, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Ostankovitch M, Guichard G, Connan F, Muller S, Chaboissier A, Hoebeke J, Choppin J, Briand JP, Guillet JG. A partially modified retro-inverso pseudopeptide modulates the cytokine profile of CTL specific for an influenza virus epitope. J Immunol 1998; 161:200-8. [PMID: 9647225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
There is considerable evidence that peptides corresponding to MHC class I-restricted epitopes can be used as immunogens or immunomodulators. Pseudopeptides containing isosteric replacements of the amide bond provide more stable analogues, which may even have enhanced biologic activity. But there have been very few studies on the use of pseudopeptides to initiate or modulate the cellular immune response. This study describes the immunogenicity of a partially modified retro-inverso pseudopeptide of an influenza virus epitope and shows that this pseudopeptide modulates the cytokine profile expressed by CD8+ CTL generated from primed precursors. Moreover, the pseudopeptide is much more efficient at low concentration than the wild-type epitope to stimulate IFN-gamma secretion by CD8+ T effector cells. These results are analyzed with reference to changes in the conformation of the MHC molecule/peptide complex deduced from molecular modeling. The findings support the idea that partially modified retro-inverso analogues can be used as altered peptide ligands to enhance the stimulation of natural epitope-specific CTL and to modify their functional properties. Hence, pseudopeptide ligands might be promising tools for use in immunotherapy.
Collapse
Affiliation(s)
- M Ostankovitch
- Laboratoire d'Immunologie des Pathologies Infectieuses et Tumorales, Institut National de la Santé et de la Recherche Médicale, U445, Université René Descartes, Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Ostankovitch M, Guichard G, Connan F, Muller S, Chaboissier A, Hoebeke J, Choppin J, Briand JP, Guillet JG. A Partially Modified Retro-Inverso Pseudopeptide Modulates the Cytokine Profile of CTL Specific for an Influenza Virus Epitope. The Journal of Immunology 1998. [DOI: 10.4049/jimmunol.161.1.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
There is considerable evidence that peptides corresponding to MHC class I-restricted epitopes can be used as immunogens or immunomodulators. Pseudopeptides containing isosteric replacements of the amide bond provide more stable analogues, which may even have enhanced biologic activity. But there have been very few studies on the use of pseudopeptides to initiate or modulate the cellular immune response. This study describes the immunogenicity of a partially modified retro-inverso pseudopeptide of an influenza virus epitope and shows that this pseudopeptide modulates the cytokine profile expressed by CD8+CTL generated from primed precursors. Moreover, the pseudopeptide is much more efficient at low concentration than the wild-type epitope to stimulate IFN-γ secretion by CD8+ T effector cells. These results are analyzed with reference to changes in the conformation of the MHC molecule/peptide complex deduced from molecular modeling. The findings support the idea that partially modified retro-inverso analogues can be used as altered peptide ligands to enhance the stimulation of natural epitope-specific CTL and to modify their functional properties. Hence, pseudopeptide ligands might be promising tools for use in immunotherapy.
Collapse
Affiliation(s)
- Marina Ostankovitch
- *Institut Cochin de Génétique Moléculaire, Laboratoire d’Immunologie des Pathologies Infectieuses et Tumorales, Institut National de la Santé et de la Recherche Médicale, U445, Université René Descartes, Paris, France; and
| | - Gilles Guichard
- †Institut de Biologie Moléculaire et Cellulaire, Immunochimie des Peptides et des Virus, UPR 9021, Centre National de la Recherche Scientifique, Strasbourg, France
| | - Francine Connan
- *Institut Cochin de Génétique Moléculaire, Laboratoire d’Immunologie des Pathologies Infectieuses et Tumorales, Institut National de la Santé et de la Recherche Médicale, U445, Université René Descartes, Paris, France; and
| | - Sylviane Muller
- †Institut de Biologie Moléculaire et Cellulaire, Immunochimie des Peptides et des Virus, UPR 9021, Centre National de la Recherche Scientifique, Strasbourg, France
| | - Aude Chaboissier
- *Institut Cochin de Génétique Moléculaire, Laboratoire d’Immunologie des Pathologies Infectieuses et Tumorales, Institut National de la Santé et de la Recherche Médicale, U445, Université René Descartes, Paris, France; and
| | - Johan Hoebeke
- †Institut de Biologie Moléculaire et Cellulaire, Immunochimie des Peptides et des Virus, UPR 9021, Centre National de la Recherche Scientifique, Strasbourg, France
| | - Jeannine Choppin
- *Institut Cochin de Génétique Moléculaire, Laboratoire d’Immunologie des Pathologies Infectieuses et Tumorales, Institut National de la Santé et de la Recherche Médicale, U445, Université René Descartes, Paris, France; and
| | - Jean-Paul Briand
- †Institut de Biologie Moléculaire et Cellulaire, Immunochimie des Peptides et des Virus, UPR 9021, Centre National de la Recherche Scientifique, Strasbourg, France
| | - Jean-Gérard Guillet
- *Institut Cochin de Génétique Moléculaire, Laboratoire d’Immunologie des Pathologies Infectieuses et Tumorales, Institut National de la Santé et de la Recherche Médicale, U445, Université René Descartes, Paris, France; and
| |
Collapse
|
22
|
Ostankovitch M, Le Gal FA, Connan F, Chassin D, Choppin J, Guillet JG. Generation of Melan-A/MART-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro. Int J Cancer 1997; 72:987-94. [PMID: 9378563 DOI: 10.1002/(sici)1097-0215(19970917)72:6<987::aid-ijc12>3.0.co;2-2] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
This study investigates the generation of primary melanoma cell-specific cytotoxic T lymphocytes (CTLs) in vitro. Induction of peptide-specific CTLs from unfractionated naive peripheral blood mononuclear cells from HLA-A2 healthy donors was assessed using 2 recently described 9-mer epitopes from the melanoma tumor antigen Melan-A/MART-1. The need for help from CD4+ T lymphocytes for the long-lasting induction of CTLs and the capacity of the peptide-induced CTL lines to recognize many melanoma cells were evaluated. CTL lines were obtained reproducibly when CD4+ T-lymphocyte help was provided during the primary stimulation either in an autologous way, in the case of tetanus toxoid antigen (TT) responder donors, or with allogeneic TT-activated T-helper cells, separated by an insert well, in the case of tetanus toxoid non-responder donors. We also investigated helper T-cell-derived factors that are produced by TT-activated lymphocytes. Our results strongly suggest that a complex network of cytokines like interleukin-2 (IL-2), interferon-gamma, IL-6 and IL-1 exerts stimulatory effects for the initiation process of CTLs. In contrast, cytokine-like IL-4 might inhibit generation of cytolytic activity if provided by TT-activated T cells at early stages of induction. Our approach can be used to generate CTLs of a desired specificity for clinical use in adoptive immunotherapy protocols.
Collapse
MESH Headings
- Antigens, Neoplasm/immunology
- Cells, Cultured
- Cytokines/biosynthesis
- Cytotoxicity, Immunologic
- HLA-A2 Antigen/biosynthesis
- Humans
- Interferon-gamma/biosynthesis
- Leukocytes, Mononuclear/cytology
- Leukocytes, Mononuclear/immunology
- Lymphocyte Activation
- MART-1 Antigen
- Melanoma/immunology
- Molecular Sequence Data
- Neoplasm Proteins/chemistry
- Neoplasm Proteins/immunology
- Oligopeptides/chemistry
- Oligopeptides/pharmacology
- Polymerase Chain Reaction
- Receptor-CD3 Complex, Antigen, T-Cell/analysis
- Receptors, Antigen, T-Cell, alpha-beta/analysis
- T-Lymphocytes, Cytotoxic/cytology
- T-Lymphocytes, Cytotoxic/immunology
- T-Lymphocytes, Helper-Inducer/immunology
- Tumor Necrosis Factor-alpha/biosynthesis
Collapse
Affiliation(s)
- M Ostankovitch
- Laboratoire d'Immunologie des Pathologies Infectieuses et Tumorales, INSERM U445, Institut Cochin de Génétique Moléculaire, Université René Descartes, Paris, France.
| | | | | | | | | | | |
Collapse
|
23
|
Buzyn A, Ostankovitch M, Zerbib A, Kemula M, Connan F, Varet B, Guillet JG, Choppin J. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol 1997; 27:2066-72. [PMID: 9295046 DOI: 10.1002/eji.1830270834] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Chronic myeloid leukemia (CML) is characterized cytogenetically by a t(9;22) translocation which generates a hybrid bcr-abl gene, encoding a p210(bcr-abl) fusion protein. The induction in vitro of leukemia-specific T cells reactive with p210(bcr-abl) is a strategy developed for an immunological therapeutic approach in CML. Peptides from the junction region of this chimeric protein have been considered as potential targets for a cytotoxic response against leukemic cells. However, only a few peptides encompassing the two p210(bcr-abl) breakpoints have been shown to bind to the most common HLA class I molecules, which limits the number of patients who could benefit from this approach. We assume that the presence of chimeric BCR-ABL protein in leukemic cells may affect processing and delivery of peptides, possibly giving rise to new epitopes at the cell surface. We selected 162 peptides from the whole sequence of this protein, including 14 peptides of the b2a2 and b3a2 junctions, which had an anchor motif for a common HLA class I molecule. We tested their ability to bind to eight HLA class I molecules (HLA-A1, -A2, -A3, -A11, -B7, -B8, -B27, -B44). We identified 48 peptides from outside the junction region, with intermediate or strong binding capacities to these HLA class I molecules contrasting with only six junction peptides with a moderate binding capacity to HLA-A3/A11, -B8, or -B44 molecules. Moreover, cytotoxic T lymphocyte lines specific for various peptides outside the junction were generated from peripheral blood mononuclear cells of HLA-A2 or -B7 healthy donors and from one CML patient. These results contribute to evaluation of immunity to the BCR-ABL chimeric protein. Further studies are required to investigate whether such epitopes are correctly processed and presented by leukemic cells.
Collapse
MESH Headings
- Amino Acid Sequence
- Binding Sites/genetics
- Cell Line
- Cell Line, Transformed
- Fusion Proteins, bcr-abl/genetics
- Fusion Proteins, bcr-abl/immunology
- HLA Antigens/metabolism
- HLA-B7 Antigen/metabolism
- Herpesvirus 4, Human
- Histocompatibility Antigens Class I/metabolism
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology
- Peptide Fragments/genetics
- Peptide Fragments/immunology
- Protein Binding
- T-Lymphocytes, Cytotoxic/immunology
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- A Buzyn
- INSERM U445, Institut Cochin de Génétique Moléculaire, Université René Descartes, Paris, France.
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Guichard G, Connan F, Graff R, Ostankovitch M, Muller S, Guillet JG, Choppin J, Briand JP. Partially modified retro-inverso pseudopeptides as non-natural ligands for the human class I histocompatibility molecule HLA-A2. J Med Chem 1996; 39:2030-9. [PMID: 8642561 DOI: 10.1021/jm9509511] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Syntheses of a series of partially modified retro-inverso analogues of the antigenic peptide M58-66 derived from the influenza virus matrix protein are reported. The retro-inverso modification phi(NH-CO) was obtained by replacement of two successive amino acid residues with a 2-substituted malonate derivative and gem-diaminoalkyl residue. The resulting compounds 1-8 were tested for their binding to the human histocompatibility class I molecule HLA-A2 in an assembly assay using lysates of peptide transporter-deficient cells T2. Specific peptide-dependent HLA-A2 assembly was revealed by an enzyme-linked immunosorbent assay. Significant HLA-A2 assembly was detected in the presence of analogues [gGly58-(S)mLeu59]-M58-66 (1a), [gGly61-(R,S)mPhe62]M58-66 (4), [gVal63-(R,S)mPhe64]M58-66 (6), and [gPhe64-(R,S)mAla65]M58-66 (7). The introduction of the retro-inverso modification between P2-P3, P3-P4, P5-P6, and P8-P9 (compounds 2, 3, 5, and 8, respectively) however led to a dramatic reduction in peptide binding to HLA-A2. Interestingly, compound 1a which contains modification between P1-P2 was found to be the most potent analogue, being able to retain the original HLA-A2 binding profile of the parent peptide M58-66. Taken together, these results and recent binding data obtained in the context of murine MHC class I molecule H-2Kd suggest that the incorporation of peptide bond surrogates in MHC class I-restricted epitopes is a useful approach to design molecules having both increased stability and high MHC-binding capacity. Depending on their agonist or antagonist effects at the T-cell receptor, such non-natural MHC ligands are likely to find many applications in the development of peptide-based vaccines or as potential therapeutic agents in the treatment of allergies and autoimmune diseases.
Collapse
Affiliation(s)
- G Guichard
- Institut de Biologie Moléculaire et Cellulaire, UPR 9021 CNRS, Strasbourg, France
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Prevost-Blondel A, Ostankovitch M, Melle J, Pannetier C, Macintyre E, Dreyfus F, Guillet JG. CDR3 size analysis of T cell receptor V beta transcripts: follow-up study in a patient with T cell acute lymphoblastic leukemia. Leukemia 1995; 9:1711-7. [PMID: 7564515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
T cell acute lymphoblastic leukemia (T-ALL) is generally considered to be a clonal disorder arising as an expansion of committed lymphoid precursors. The generation of functional T cell receptor (TCR) genes involves DNA rearrangement processes. This predisposes immature lymphoid cells to abnormal rearrangements. Previous analysis of the TCR genes strongly suggested the clonal origin of human T-ALL. We present a sensitive clonal analysis of bone marrow TCR V beta transcripts in a case of T-ALL. This study allows the analysis not only of TCR V beta transcripts in tumor cells but also the temporal modification of the global TCR repertoire in the follow-up of clinical specimens from bone marrow aspirates. Moreover, we used clone-specific junctional region oligonucleotide probes corresponding to the clonal leukemic population for the molecular monitoring of the malignant clone throughout the clinical course of the disease. This molecular fingerprint appears to be a sensitive method to detect minimal residual disease. It shows that junctional regions of rearranged TCR beta genes corresponding to the tumor cells can also be detected at the time of the complete remission.
Collapse
Affiliation(s)
- A Prevost-Blondel
- Unité d'Immunologie des Interactions Cellulaires et Moléculaires, Institut Cochin de Génétique Moléculaire, INSERM U.152, Paris, France
| | | | | | | | | | | | | |
Collapse
|
26
|
Ostankovitch M, Choppin J, Guillet JG. [Tumor cell antigenicity: cancers and vaccines]. Rev Prat 1995; 45:1921-6. [PMID: 8525301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Tumor-specific immunity is partly linked to the observation that cancerous cells express some proteins that are not present in normal cells. In the past, one of the major problems for the development of immunotherapy approaches has been linked to the difficulty to identify the antigens which are the targets of the tumor-specific T cells. Recent progress in fundamental immunology, particularly concerning the understanding of the molecular basis of cellular immunity, has facilitated the identification of tumor-specific antigens. These results allow to study new therapeutic approaches today.
Collapse
Affiliation(s)
- M Ostankovitch
- Unité d'immunologie des interactions cellulaires et moléculaires, Institut Cochin de génétique moléculaire, INSERM U.152, Paris
| | | | | |
Collapse
|
27
|
Houlgatte R, Scarmato P, el Marhomy S, Martin M, Ostankovitch M, Lafosse S, Vervisch A, Auffray C, Platier-Tonneau D. HLA class II antigens and the HIV envelope glycoprotein gp120 bind to the same face of CD4. J Immunol 1994; 152:4475-88. [PMID: 7512597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Although the HIV gp120 binding site of CD4 is well characterized, its interaction site with HLA class II molecules is still controversial. Sixty-seven mutations within the four extracellular domains of CD4 were examined for their effects on cell surface expression and conformational changes and for adhesion of HLA class II-expressing B lymphocytes and HIV gp120 binding to CD4-transfected COS cells. Mutations within the gp120 binding site affected both assays similarly, indicating that the two sites fully overlap. A few additional substitutions of residues mapping on the same face of domains 1 and 2 induced decreased rosette formation. Molecular modeling studies indicated that this is likely to be the consequence of conformational changes induced by the mutations. Thus, CD4 appears to interact with HLA class II molecules mainly through the HIV gp120 binding site and possibly through a second minor interaction site mapping on the same face of the molecule.
Collapse
Affiliation(s)
- R Houlgatte
- Unité de Génétique Moléculaire et de Biologie du Développement UPR 420, Centre National de la Recherche Scientifique, Villejuif, France
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Houlgatte R, Scarmato P, el Marhomy S, Martin M, Ostankovitch M, Lafosse S, Vervisch A, Auffray C, Platier-Tonneau D. HLA class II antigens and the HIV envelope glycoprotein gp120 bind to the same face of CD4. The Journal of Immunology 1994. [DOI: 10.4049/jimmunol.152.9.4475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Abstract
Although the HIV gp120 binding site of CD4 is well characterized, its interaction site with HLA class II molecules is still controversial. Sixty-seven mutations within the four extracellular domains of CD4 were examined for their effects on cell surface expression and conformational changes and for adhesion of HLA class II-expressing B lymphocytes and HIV gp120 binding to CD4-transfected COS cells. Mutations within the gp120 binding site affected both assays similarly, indicating that the two sites fully overlap. A few additional substitutions of residues mapping on the same face of domains 1 and 2 induced decreased rosette formation. Molecular modeling studies indicated that this is likely to be the consequence of conformational changes induced by the mutations. Thus, CD4 appears to interact with HLA class II molecules mainly through the HIV gp120 binding site and possibly through a second minor interaction site mapping on the same face of the molecule.
Collapse
Affiliation(s)
- R Houlgatte
- Unité de Génétique Moléculaire et de Biologie du Développement UPR 420, Centre National de la Recherche Scientifique, Villejuif, France
| | - P Scarmato
- Unité de Génétique Moléculaire et de Biologie du Développement UPR 420, Centre National de la Recherche Scientifique, Villejuif, France
| | - S el Marhomy
- Unité de Génétique Moléculaire et de Biologie du Développement UPR 420, Centre National de la Recherche Scientifique, Villejuif, France
| | - M Martin
- Unité de Génétique Moléculaire et de Biologie du Développement UPR 420, Centre National de la Recherche Scientifique, Villejuif, France
| | - M Ostankovitch
- Unité de Génétique Moléculaire et de Biologie du Développement UPR 420, Centre National de la Recherche Scientifique, Villejuif, France
| | - S Lafosse
- Unité de Génétique Moléculaire et de Biologie du Développement UPR 420, Centre National de la Recherche Scientifique, Villejuif, France
| | - A Vervisch
- Unité de Génétique Moléculaire et de Biologie du Développement UPR 420, Centre National de la Recherche Scientifique, Villejuif, France
| | - C Auffray
- Unité de Génétique Moléculaire et de Biologie du Développement UPR 420, Centre National de la Recherche Scientifique, Villejuif, France
| | - D Platier-Tonneau
- Unité de Génétique Moléculaire et de Biologie du Développement UPR 420, Centre National de la Recherche Scientifique, Villejuif, France
| |
Collapse
|